

Amendments to the Claims

The following claim listing replaces all previous claim listings in the application:

1-26. (Cancelled)

27. (Currently Amended) A method of treatment of allergy and asthma patients in need of [multiple drugs daily] such treatment, comprising administering [the] a pharmaceutical composition [of claim 25] consisting essentially of glycophosphopeptical in multiple doses for a short term [course] treatment period of [1-14] 1-20 days to induce a remission of [3-12] several months during which further treatment is not necessary.

28. (Withdrawn) A pharmaceutical composition for the treatment of allergy and asthma consisting essentially of the herbal seeds of Nigella sativa to act as a vaccine that is almost identical to Purified Protein Derivative from Bacillus Calmette Guréin:

- i- Switch-off the airway eosinophilic inflammation.
- ii- Reduce mucus secretion.
- iii- Reduce symptom scores significantly.
- iv- Restore airways patency as measured by Pulmonary Function Test.

29. (Withdrawn) A pharmaceutical composition vaccine of claim 28, to induce a clinical remission and long-term therapeutic effect in a chronically ill patient suffering from asthma and allergy.

30. (Withdrawn) A method of treatment of allergy and asthma patients in need of multiple drugs daily, comprising of administering the pharmaceutical composition of claim 28 for a short course of 1-14 days to induce a remission of 3-12 months.

31. (Withdrawn) A pharmaceutical composition vaccine from Nigella sativa, to induce a clinical remission and long-term therapeutic effect in patients with Crohn's disease.
32. (Withdrawn) A method of treatment of Crohn's disease, comprising of administering the pharmaceutical composition vaccine from Nigella sativa for a short course of 1-14 days to induce symptomatic remission.
33. (Withdrawn) A pharmaceutical composition vaccine from Nigella sativa, to induce a clinical remission and long-term therapeutic effect in patients with influenza and common cold.
34. (Withdrawn) A method of treatment of influenza and common cold, comprising of administering the pharmaceutical composition vaccine from Nigella sativa for a short course of 1-14 days to induce symptomatic remission.
35. (New) The method of claim 27 wherein the short term treatment period lasts 3-5 days.
36. (New) The method of claim 27 wherein the glycophosphopeptical is administered in doses up to 2000mg.
37. (New) The method of claim 27 wherein the glycophosphopeptical is administered in doses of 200-1000mg.
38. (New) The method of claim 27 wherein the glycophosphopeptical is administered in doses at least once daily up to 10 times daily.

39. (New) The method of claim 27 wherein the glycophosphopeptical is administered orally as capsules, tablets, lozenges, a powder or a syrup.

40. (New) The method of claim 27 wherein the glycophosphopeptical is administered topically in the form of eye or nasal preparations such as drops or ointment, or skin or vaginal preparations such as cream and ointment.

41. (New) The method of claim 27 for the treatment of patients suffering from extrinsic asthma, intrinsic asthma or mixed extrinsic/intrinsic asthma.

42. (New) The method of claim 27 for the treatment of patients suffering from allergic and perennial rhinitis, allergic conjunctivitis, chronic urticaria, atopic dermatitis or laryngeal oedema.

43. (New) The method of claim 37 of treating patients suffering from chronic corticosteroid-dependent allergy and asthma.